The thesis of this innovative and challenging book, first published in 2001, is that brain drug development has been restricted by the failure of adequate brain drug targeting, and that this is an increasingly urgent problem as developments in genomics lead to new generations of therapeutic macromolecules. The author, a world leader in the study of the blood-brain barrier and its clinical implications, reviews the field of neurotherapeutics from the point of view of drug targeting. He surveys the scientific and clinical basis of drug delivery across biological membranes, including topics such as genetically engineered trojan horses for drug targeting, antisense neurotherapeutics, and gene therapy of brain disorders. At a time when there are few significant new drug treatments in prospect for common neurological diseases, this authoritative review will encourage a wide range of clinicians and neuroscientists to reexamine the development and use of drugs in treating disorders of the central nervous system.
"synopsis" may belong to another edition of this title.
Review of the hardback: '... a book that will become a standard on drug targeting to the brain ... a must for everybody who works in the field of brain drug delivery in academia as well as in the pharmaceutical industry.' W. Kamphorst, www.bmjbookshop.com
Review of the hardback: 'This book provides an extensive review of brain drug targeting of large molecules and will be a valuable reference to those interested in completing research in this field.' Tejal Patel, Doody's Health Sciences Book Review Journal
Review of the hardback: 'This is an excellent book to be expected from a major researcher in the field. The lucid text is illuminated by an eclectic mix of diagrams and plates that will have a broad appeal to a wide audience.' A. Davenport, British Journal of Neurosurgery
This challenging 2001 book reviews modern neurotherapeutics from the point of view of drug targeting, surveying the scientific and clinical basis of drug delivery across biological membranes. It will encourage a wide range of clinicians and neuroscientists to reexamine the use of drugs in treating disorders of the central nervous system.
"About this title" may belong to another edition of this title.
Seller: Labyrinth Books, Princeton, NJ, U.S.A.
Condition: Very Good. Seller Inventory # 061850
Seller: Revaluation Books, Exeter, United Kingdom
Hardcover. Condition: Brand New. 1st edition. 353 pages. 10.00x7.00x1.00 inches. In Stock. This item is printed on demand. Seller Inventory # __0521800773
Quantity: 1 available
Seller: GreatBookPrices, Columbia, MD, U.S.A.
Condition: New. Seller Inventory # 701988-n
Seller: Grand Eagle Retail, Bensenville, IL, U.S.A.
Hardcover. Condition: new. Hardcover. The thesis of this innovative and challenging book is that brain drug development has been restricted by the failure of adequate brain drug targeting, and that this is an increasingly urgent problem as developments in genomics lead to new generations of therapeutic macromolecules. The author, a world leader in the study of the blood-brain barrier and its clinical implications, reviews the field of neurotherapeutics from the point of view of drug targeting. He surveys the scientific and clinical basis of drug delivery across biological membranes, including topics such as genetically engineered trojan horses for drug targeting, antisense neurotherapeutics, and gene therapy of brain disorders. At a time when there are few significant new drug treatments in prospect for common neurological diseases, this authoritative review will encourage a wide range of clinicians and neuroscientists to reexamine the development and use of drugs in treating disorders of the central nervous system. This challenging book reviews modern neurotherapeutics from the point of view of drug targeting, surveying the scientific and clinical basis of drug delivery across biological membranes. It will encourage a wide range of clinicians and neuroscientists to reexamine the use of drugs in treating disorders of the central nervous system. This item is printed on demand. Shipping may be from multiple locations in the US or from the UK, depending on stock availability. Seller Inventory # 9780521800778
Seller: GreatBookPrices, Columbia, MD, U.S.A.
Condition: As New. Unread book in perfect condition. Seller Inventory # 701988
Seller: GreatBookPricesUK, Woodford Green, United Kingdom
Condition: As New. Unread book in perfect condition. Seller Inventory # 701988
Quantity: Over 20 available
Seller: GreatBookPricesUK, Woodford Green, United Kingdom
Condition: New. Seller Inventory # 701988-n
Quantity: Over 20 available
Seller: moluna, Greven, Germany
Gebunden. Condition: New. This challenging 2001 book reviews modern neurotherapeutics from the point of view of drug targeting, surveying the scientific and clinical basis of drug delivery across biological membranes. It will encourage a wide range of clinicians and neuroscientists . Seller Inventory # 594761543
Quantity: Over 20 available
Seller: CitiRetail, Stevenage, United Kingdom
Hardcover. Condition: new. Hardcover. The thesis of this innovative and challenging book is that brain drug development has been restricted by the failure of adequate brain drug targeting, and that this is an increasingly urgent problem as developments in genomics lead to new generations of therapeutic macromolecules. The author, a world leader in the study of the blood-brain barrier and its clinical implications, reviews the field of neurotherapeutics from the point of view of drug targeting. He surveys the scientific and clinical basis of drug delivery across biological membranes, including topics such as genetically engineered trojan horses for drug targeting, antisense neurotherapeutics, and gene therapy of brain disorders. At a time when there are few significant new drug treatments in prospect for common neurological diseases, this authoritative review will encourage a wide range of clinicians and neuroscientists to reexamine the development and use of drugs in treating disorders of the central nervous system. This challenging book reviews modern neurotherapeutics from the point of view of drug targeting, surveying the scientific and clinical basis of drug delivery across biological membranes. It will encourage a wide range of clinicians and neuroscientists to reexamine the use of drugs in treating disorders of the central nervous system. This item is printed on demand. Shipping may be from our UK warehouse or from our Australian or US warehouses, depending on stock availability. Seller Inventory # 9780521800778
Quantity: 1 available
Seller: Revaluation Books, Exeter, United Kingdom
Hardcover. Condition: Brand New. 1st edition. 353 pages. 10.00x7.00x1.00 inches. In Stock. Seller Inventory # x-0521800773
Quantity: 2 available